RS67706B1 - Čvrsti oblici 2-(5-(4-(2-morfolinoetoksi)fenil)piridin-2-il)-n-benzilacetamida - Google Patents
Čvrsti oblici 2-(5-(4-(2-morfolinoetoksi)fenil)piridin-2-il)-n-benzilacetamidaInfo
- Publication number
- RS67706B1 RS67706B1 RS20251351A RSP20251351A RS67706B1 RS 67706 B1 RS67706 B1 RS 67706B1 RS 20251351 A RS20251351 A RS 20251351A RS P20251351 A RSP20251351 A RS P20251351A RS 67706 B1 RS67706 B1 RS 67706B1
- Authority
- RS
- Serbia
- Prior art keywords
- exemplary embodiment
- compound
- solvent
- weeks
- approximately
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555390P | 2017-09-07 | 2017-09-07 | |
| EP18854688.1A EP3679016B1 (en) | 2017-09-07 | 2018-09-07 | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide |
| PCT/US2018/049829 WO2019051147A1 (en) | 2017-09-07 | 2018-09-07 | SOLID FORMS OF 2- (5- (4- (2-MORPHOLINOETHOXY) PHENYL) PYRIDIN-2-YL) -N-BENZYLACETAMIDE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS67706B1 true RS67706B1 (sr) | 2026-02-27 |
Family
ID=65517772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20251351A RS67706B1 (sr) | 2017-09-07 | 2018-09-07 | Čvrsti oblici 2-(5-(4-(2-morfolinoetoksi)fenil)piridin-2-il)-n-benzilacetamida |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US10669236B2 (enExample) |
| EP (2) | EP4674486A3 (enExample) |
| JP (3) | JP7843116B2 (enExample) |
| KR (2) | KR102691700B1 (enExample) |
| CN (2) | CN111278808B (enExample) |
| AU (2) | AU2018330163B2 (enExample) |
| BR (1) | BR112020004419A2 (enExample) |
| CA (1) | CA3074831A1 (enExample) |
| DK (1) | DK3679016T3 (enExample) |
| ES (1) | ES3056703T3 (enExample) |
| FI (1) | FI3679016T3 (enExample) |
| HR (1) | HRP20260002T1 (enExample) |
| IL (2) | IL326637A (enExample) |
| LT (1) | LT3679016T (enExample) |
| MX (2) | MX2020002622A (enExample) |
| PL (1) | PL3679016T3 (enExample) |
| PT (1) | PT3679016T (enExample) |
| RS (1) | RS67706B1 (enExample) |
| SG (1) | SG11202001868RA (enExample) |
| SI (1) | SI3679016T1 (enExample) |
| SM (1) | SMT202500467T1 (enExample) |
| TW (1) | TWI815820B (enExample) |
| WO (1) | WO2019051147A1 (enExample) |
| ZA (1) | ZA202106139B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968574B2 (en) * | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| EP4186890A1 (en) | 2021-11-29 | 2023-05-31 | Moehs Ibérica, S.L. | Preparation of n-benzyl-2-(5-bromo-pyridin-2-yl)-acetamide for the synthesis of tirbanibulin |
| CN115010655A (zh) * | 2022-07-21 | 2022-09-06 | 重庆迈德凯医药有限公司 | 一种替尼布林的纯化方法 |
| WO2026022219A1 (en) | 2024-07-24 | 2026-01-29 | Almirall, S.A. | Injectable formulations comprising tirbanibulin |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US7141593B1 (en) * | 1999-06-04 | 2006-11-28 | Abbott Laboratories | Pharmaceutical formulations |
| DE60209704T2 (de) * | 2001-05-22 | 2006-11-16 | Pfizer Products Inc., Groton | Neue kristallforme von azithromycin |
| US6821502B2 (en) * | 2002-06-12 | 2004-11-23 | Chevron U.S.A. Inc. | Method of making aluminum-containing zeolite with IFR structure |
| US7351833B2 (en) * | 2004-07-23 | 2008-04-01 | Abbott Laboratories | (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate |
| US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| PL1836169T3 (pl) | 2004-12-28 | 2012-07-31 | Kinex Pharmaceuticals Llc | Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek |
| MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| DE602006019822D1 (de) * | 2005-09-13 | 2011-03-10 | Sicor Inc | Reines rocuroniumbromid |
| ES2500165T3 (es) * | 2006-06-29 | 2014-09-30 | Kinex Pharmaceuticals, Llc | Composiciones de biarilo y métodos para modular una cascada de quinasas |
| KR20090064400A (ko) * | 2006-09-28 | 2009-06-18 | 머크 앤드 캄파니 인코포레이티드 | Ｈｄａｃ 억제제 및 킬레이트화 가능한 금속 화합물 및 금속-ｈｄａｃ 억제제 킬레이트 착물의 약제학적 조성물 |
| US7837978B2 (en) * | 2006-10-13 | 2010-11-23 | Chevron U.S.A. Inc. | Process for preparing aluminum-containing molecular sieve SSZ-26 |
| PE20081506A1 (es) * | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
| US7935697B2 (en) * | 2006-12-28 | 2011-05-03 | Kinex Pharmaceuticals, Llc | Compositions for modulating a kinase cascade and methods of use thereof |
| TWI457336B (zh) * | 2006-12-28 | 2014-10-21 | Kinex Pharmaceuticals Llc | 調節激酶級聯之組成物及方法 |
| US7939529B2 (en) | 2007-05-17 | 2011-05-10 | Kinex Pharmaceuticals, Llc | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
| EP2160394A1 (en) * | 2007-05-22 | 2010-03-10 | Ultimorphix Technologies B.v. | Tenofovir disoproxil hemi-fumaric acid co-crystal |
| WO2015069217A1 (en) * | 2013-11-05 | 2015-05-14 | Baylor College Of Medicine | Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis |
| CN106810490A (zh) * | 2017-02-06 | 2017-06-09 | 重庆泰润制药有限公司 | 一种二芳基化合物的晶型及其制备方法和应用 |
| SI3592355T1 (sl) | 2017-03-10 | 2026-04-30 | Atnx Spv, Llc | KX2-391/KX-01 za uporabo pri zdravljenju aktinične keratoze |
-
2018
- 2018-09-06 IL IL326637A patent/IL326637A/en unknown
- 2018-09-07 ES ES18854688T patent/ES3056703T3/es active Active
- 2018-09-07 EP EP25201944.3A patent/EP4674486A3/en active Pending
- 2018-09-07 DK DK18854688.1T patent/DK3679016T3/da active
- 2018-09-07 PL PL18854688.1T patent/PL3679016T3/pl unknown
- 2018-09-07 JP JP2020536496A patent/JP7843116B2/ja active Active
- 2018-09-07 EP EP18854688.1A patent/EP3679016B1/en active Active
- 2018-09-07 RS RS20251351A patent/RS67706B1/sr unknown
- 2018-09-07 CN CN201880069894.6A patent/CN111278808B/zh active Active
- 2018-09-07 PT PT188546881T patent/PT3679016T/pt unknown
- 2018-09-07 MX MX2020002622A patent/MX2020002622A/es unknown
- 2018-09-07 SG SG11202001868RA patent/SG11202001868RA/en unknown
- 2018-09-07 BR BR112020004419-9A patent/BR112020004419A2/pt active IP Right Grant
- 2018-09-07 LT LTEPPCT/US2018/049829T patent/LT3679016T/lt unknown
- 2018-09-07 CA CA3074831A patent/CA3074831A1/en active Pending
- 2018-09-07 US US16/124,281 patent/US10669236B2/en active Active
- 2018-09-07 WO PCT/US2018/049829 patent/WO2019051147A1/en not_active Ceased
- 2018-09-07 HR HRP20260002TT patent/HRP20260002T1/hr unknown
- 2018-09-07 SI SI201831281T patent/SI3679016T1/sl unknown
- 2018-09-07 FI FIEP18854688.1T patent/FI3679016T3/fi active
- 2018-09-07 KR KR1020207010105A patent/KR102691700B1/ko active Active
- 2018-09-07 TW TW107131540A patent/TWI815820B/zh active
- 2018-09-07 SM SM20250467T patent/SMT202500467T1/it unknown
- 2018-09-07 KR KR1020247025684A patent/KR20240119192A/ko active Pending
- 2018-09-07 CN CN202410415705.3A patent/CN118439992A/zh active Pending
- 2018-09-07 AU AU2018330163A patent/AU2018330163B2/en active Active
-
2020
- 2020-03-01 IL IL272992A patent/IL272992A/en unknown
- 2020-03-06 MX MX2023001805A patent/MX2023001805A/es unknown
- 2020-04-27 US US16/858,854 patent/US11230527B2/en active Active
-
2021
- 2021-08-25 ZA ZA2021/06139A patent/ZA202106139B/en unknown
- 2021-12-09 US US17/546,133 patent/US12215083B2/en active Active
-
2023
- 2023-02-21 AU AU2023201010A patent/AU2023201010B2/en active Active
- 2023-06-30 JP JP2023107781A patent/JP2023157909A/ja active Pending
-
2024
- 2024-12-19 US US18/987,655 patent/US20250115555A1/en active Pending
-
2025
- 2025-06-02 JP JP2025091579A patent/JP2025131661A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12215083B2 (en) | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide | |
| CA3047776C (en) | Preparation, uses and solid forms of obeticholic acid | |
| TW201443001A (zh) | 雙環止痛化合物 | |
| CN110461836B (zh) | 一种选择性抑制激酶化合物及其用途 | |
| JP2026041824A (ja) | テガビビントの結晶形態、調製方法、及びその使用 | |
| TWI771280B (zh) | 經取代之5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式 | |
| JP6961348B2 (ja) | 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型 | |
| RU2802964C2 (ru) | Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида | |
| HK40131421A (en) | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide | |
| JP7184302B2 (ja) | ヒトトレフォイル因子３の阻害に有用な化合物 | |
| TWI898321B (zh) | 用於治療或預防高尿酸血症或痛風的化合物的固體晶型 | |
| CN105566302A (zh) | 二氢吲哚酮化合物及其盐的结晶 | |
| CA3101143A1 (en) | Salt form | |
| CN102666528A (zh) | 晶体cdc7 抑制剂盐 | |
| CA3257458A1 (en) | SOLID FORMS OF A COMPOUND FOR TREATING OR PREVENTING HYPERURICEMIA OR GOUT | |
| CN121941687A (zh) | 一种丙烯酰胺类化合物的晶型vi及其制备方法和用途 |